Lpath Inc (LPTN.OQ) Quote| Reuters.com
United States

Lpath Inc (LPTN.OQ)

LPTN.OQ on NASDAQ Stock Exchange Capital Market

27 Jun 2016
Change (% chg)

$-0.13 (-5.96%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for LPTN.OQ


Lpath, Inc. is a biotechnology company. The Company is focused on the discovery and development of lipidomic-based therapeutic antibodies. The Company's product candidates include iSONEP, ASONEP and Lpathomab. The Company utilizes ImmuneY2 technology for the production of its antibodies. iSONEP is the ocular formulation of... (more)
No analyst recommendations are available for LPTN.OQ.


Beta: 0.52
Market Cap(Mil.): $5.15
Shares Outstanding(Mil.): 2.36
Dividend: --
Yield (%): --


  LPTN.OQ Industry Sector
P/E (TTM): -- 38.82 34.11
EPS (TTM): -4.67 -- --
ROI: -80.80 -5.72 14.23
ROE: -83.08 -4.83 15.46

BRIEF-Lpath awarded department of defense grant

* Lpath awarded department of defense grant for traumatic brain injury pain study

Jun 20 2016

BRIEF-Lpath announces 1-for-14 reverse stock split

* Number of common shares outstanding will be decreased from approximately 33.1 million pre-split to 2.36 million shares post-split

Jun 09 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Thomson Reuters Stock Report
Provider : Reuters Investment Profile
Provider : Pechala's Reports
Provider : Wright Reports
Provider : Thomson Reuters Stock Report

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.